Prostate cancer screening: A survey of attitudes and practices among finnish physicians in 1999 and 2007

Journal of Medical Screening

Volumn 18, Issue 1, 2011, Pages 46-49

  Pogodin Hannolainen, Dimitri ^a,e   Juusela, Harri ^b   Tammela, Teuvo L J ^a   Ruutu, Mirja ^b   Aro, Jussi ^b   Määttänen, Liisa ^c   Auvinen, Anssi ^d  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c FINNISH CANCER REGISTRY   (Finland)

^d UNIVERSITY OF TAMPERE   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CLINICAL PRACTICE; EARLY DIAGNOSIS; FINLAND; HUMAN; MALE; METABOLISM; PHYSICIAN; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; STATISTICS; UTILIZATION REVIEW;

EARLY DETECTION OF CANCER; FINLAND; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES;

EID: 79955623063     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1258/jms.2010.010090     Document Type: Article

References (25)

1. Stenman UH, Leinonen J, Zhang WH, Finne P. Prostate-specific antigen. Semin Cancer Biol 1999;9:83-93 (Pubitemid 29265524)
2. Teahan SJ, Klotz LH. Current role of prostate-specific antigen kinetics in managing patients with prostate cancer. BJU Int 2006;97:451-5
3. Melia J. Part 1: The burden of prostate cancer, its natural history, information on the outcome of screening and estimates of ad hoc screening with particular reference to England and Wales. BJU Int 2005;95:4-15 (Pubitemid 40547263)
4. Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among US men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008;17:636-44 (Pubitemid 351469214)
5. Melia J, Moss S. Survey of the rate of PSA testing in general practice. Br J Cancer 2001;85:656-7 (Pubitemid 32929459)
6. Gavin A, McCarron P, Middleton RJ, et al. Evidence of prostate cancer screening in a UK region. BJU Int 2004;93:730-4 (Pubitemid 38497019)
7. Russo A, Autelitano M, Bellini A, Bisanti L. Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in metropolitan area of northern Italy. J Med Screen 2002;9:179-80 (Pubitemid 36135345)
8. American Urological Association. Prostate-specific antigen (PSA) best practice policy. Oncology (Huntington) 2000;14:267-80
9. Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2010: a review of current American Cancer Society Guidelines and issues in cancer screening. CA Cancer J Clin 2010;60:99-119
10. Schröder FH, Roobol M, Hugosson J, et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8
11. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate cancer screening trial. N Engl J Med 2009;360:1310-9
12. Määttänen L, Auvinen A, Stenman U-H, et al. European randomized study of prostate cancer screening: first year results of the Finnish trial. Br J Cancer 1999;79:1210-4 (Pubitemid 29087900)
13. Edlefsen KL, Mandelson MT, McIntosh MW, Andersen MR, Wagner EH, Urban N. Prostate-specific antigen for prostate cancer screening. Do physician characteristics affect its use? Am J Prev Med 1999;17:87-90 (Pubitemid 29325062)
14. Drummond FJ, Carsin A-E, Sharp L, Comber H. Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners. BMC Fam Pract 2009;10:3
15. Lawson DA, Simoes EJ, Sharp D, Murayi T, Hagan R, Brownson RC, Wilkerson J. Prostate cancer screening - a physician survey in Missouri. J Community Health 1998;23:347-8
16. Bunting PS, Goel V, Williams JI, Iscoe NA. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer. CMAJ 1999;160:70-5 (Pubitemid 29054232)
17. McNaughton Collins M, Stafford RS, Barry MJ. Age-specific patterns of prostate-specific antigen testing among primary care physician visits. J Fam Pract 2000;49:169-72
18. Steele CB, Miller DS, Maylahn C, Uhler RJ, Baker CT. Knowledge, attitudes, and screening practices among older men regarding prostate cancer. Am J Public Health 2000;90:1595-600
19. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:192-9
20. Kilpeläinen TP, Tammela TLJ, Määttänen L, et al. False-positive screening results in the Finnish prostate cancer trial. Br J Cancer 2010;102:469-74
21. Ciatto S, Zappa M, Villers A, Paez A, Otto SJ, Auvinen A. Contamination by opportunistic screening in the European Randomised Study of Prostate Cancer Screening. BJU Int 2003;92 Suppl 2:97-100 (Pubitemid 38091150)
22. Otto SJ, van der Cruusen IW, Liem MK, et al. Effective PSA contamination in the Rotterdam section of the European randomised study of screening for prostate cancer. Int J Cancer 2003;105:394-9 (Pubitemid 36570054)
23. Paez A, Lujan M, Llanes L, et al. PSA use in a Spanish industrial area. Eur Urol 2002;21:1-5
24. de Konning HJ, Liem MK, Baan CA, et al. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) Trial. Int J Cancer 2002;98:268-73 (Pubitemid 34150812)
25. Brett J, Watson E, Hewitson P, et al. PSA testing for prostate cancer: an online survey of the views and reported practice of general practitioners in the UK. BMC Fam Pract 2005;6:24